alexa Mark Guthridge | sample
ISSN: 2329-8790

Journal of Hematology & Thromboembolic Diseases
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mark Guthridge

Mark Guthridge Mark Guthridge
Department of Clinical Haematology
Australian Centre for Blood Diseases (ACBD)
Monash University
Tel: 61 3 9903 0652
Fax: 61 3 9903 0228

Dr. Mark Guthridge completed his Ph.D studies at Monash University after which he took up a postdoctoral position at New York University Medical Centre as a Darland Fellow. He returned to the Institute of Medical and Veterinary Science, Adelaide Australia in 1998 and was awarded a Peter Nelson Leukaemia Research Fellowship to examine molecular approaches for the therapeutic targeting of acute myeloid leukemic (AML) cells. In 2011 Dr. Guthridge moved his laboratory to the Division of Blood Cancers at the Australian Centre for Blood Diseases (ACBD) located on the Alfred Medical Research and Education Precinct (AMREP) in Melbourne.

Since 2000, his lab has received continual funding from International (NIH, AICR), National (NH&MRC, LFA) and State agencies (Cancer Council of SA).  His work has been published in leading journals including Cell, Molecular Cell, Cell Stem Cell and EMBO J as well as specialist cancer/hemopoietic journals such as Blood, Leukemia and Cancer Research. Dr. Guthridge regularly serves of NH&MRC GRPs and is co-convenor of the New Directions in Leukaemia Research (NDLR) conference held biennially on the Sunshine Coast, QLD.

Research Interest

Dr. Guthridge’s research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Guthridge’s laboratory seeks to identify new therapeutic targets in leukaemia.


Global Speakers in the subject

Global Experts in the subject


The Regulation of Mitochondrial Metabolism by the Bcl-2 Family of Pro-Survival Proteins: New Therapeutic Opportunities for Targeting Cancer Cells
Andrew H Wei, Mellissa Brown and Mark Guthridge
Review Article: J Hematol Thrombo Dis 2013, 1:121
DOI: 10.4172/2329-8790.1000121
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version